Management guidelines for use alemtuzumab in B-cell chronic lymphocytic leukemia

Clinical Lymphoma

Volumn 4, Issue 4, 2004, Pages 220-227

  Keating, Michael ^a   Coutré, Stephen ^b   Rai, Kanti ^c   Österborg, Anders ^g   Faderl, Stefan ^a   Kennedy, Ben ^h   Kipps, Tom ^d   Bodey, Gerald ^a   Byrd, John C ^e   Rosen, Steven ^f   Dearden, Claire ⁱ   Dyer, Martin J S ^e   Hillmen, Peter ^j  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h UNIVERSITY OF LEICESTER   (United Kingdom)

ⁱ ST GEORGE S HOSPITAL   (United Kingdom)

^j PINDERFIELDS GENERAL HOSPITAL   (United Kingdom)

more..

Author keywords

Bone marrow involvement; Cytomegalovirus; Infections; Infusional side effects; Lymphocytosis; Mimimal residual disease; Neutropenia

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ATOVAQUONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHLORPHENIRAMINE; CIMETIDINE; CORTICOSTEROID; COTRIMOXAZOLE; DAPSONE; DIPHENHYDRAMINE; ERYTHROPOIETIN; FAMCICLOVIR; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROCORTISONE; PARACETAMOL; PENTAMIDINE; PETHIDINE; RANITIDINE; SEROTONIN ANTAGONIST; STEROID; UNINDEXED DRUG; VALACICLOVIR;

ANEMIA; B CELL LEUKEMIA; BACTERIAL PNEUMONIA; BLOOD TOXICITY; BONE MARROW DISEASE; CANCER COMBINATION CHEMOTHERAPY; CATHETER INFECTION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PRACTICE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ERADICATION THERAPY; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPOTENSION; INFECTION PREVENTION; INJECTION PAIN; INTERSTITIAL PNEUMONIA; LYMPHOCYTOSIS; MAINTENANCE THERAPY; MINIMAL RESIDUAL DISEASE; MYCOSIS; NAUSEA; NEUTROPENIA; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; REVIEW; RIGOR; SEPSIS; SIDE EFFECT; SKIN EDEMA; SKIN MANIFESTATION; THROMBOCYTOPENIA; TREATMENT PLANNING; URTICARIA; VIRUS REACTIVATION; VOMITING;

EID: 11144357712     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2004.n.002     Document Type: Review

References (21)

1. O'Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001; 19:1414-1420.
2. Perkins JG, Flynn JM, Howard RS, et al. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 2002; 94:2033-2039.
3. Keating M, O'Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002; 43:1755-1762.
4. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99:3554-3561.
5. Kalil N, Cheson BD. Management of chronic lymphocytic leukaemia. Drugs Aging 2000; 16:9-27.
6. Rai K, Freter CB, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20:3891-3897.
7. Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993; 82:807-812.
8. Kennedy B, Rawstron AC, Carter C, et al. Campath-1H with fludarabine: a novel, highly active combination in refractory CLL. Blood 2000; 96(suppl):289b (Abstract #4991).
9. O'Brien SM, Thomas DA, Cortes J, et al. Campath-1H for minimal residual disease in CLL. Proc Am Soc Clin Oncol 2001; 20(suppl):284a (Abstract #1132).
10. Dyer MJ, Kelsey SM, Mackay HJ, et al. In vivo 'purging' of residual disease in CLL with Campath-1H. Br J Haematol 1997;97:669-672.
11. Kennedy B, Rawstron AC, Evans P, et al. Campath-1H therapy in 29 patients with refractory CLL: 'true' complete remission is an attainable goal. Blood 1999; 94(suppl):603a (Abstract #2683).
12. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia. Blood 2002; 100:768-773.
13. Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999; 354:1691-1695.
14. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997; 15:1567-1574.
15. Cao TM, Nguyen DD, Dugan K, et al. Incidence of cytomegalovirus (CMV) viremia during Campath-1H therapy for relapsed/refractory chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL). Blood 2001; 98(suppl):366a (Abstract #1540).
16. Williams TE, Roach J, Rugg T, et al. Frequency of cytomegalovirus pneumonia following alemtuzumab (Campath®) treatment in lymphoid malignancies: review of 1538 patients. Blood 2001; 98(suppl):249b (Abstract #4923).
17. Montillo M, Cafro AM, Tedeschi A, et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica 2002; 87:695-700.
18. Bowen AL, Zomas A, Emmett E, et al. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol 1997; 96:617-619.
19. Osterborg A, Fassas AS, Anagnostopoulos A, et al. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 1996; 93:151-153.
20. Hoffman M, Jansen D, Rai K. Analysis of response to Campath-1H in patients with B-CLL progressing after fludarabine therapy. Hematol Cell Ther 1999;42(suppl):67-68 (Abstract #P129).
21. Pangalis GA, Dimopoulou MN, Angelopoulou MK, et al. Campath-1H in B-chronic lymphocytic leukemia: report on a patient treated thrice in a 3 year period. Med Oncol 2000; 17:70-73.